Regulatory Peptides, 40 (1992) 422–423
© 1992 Elsevier Science Publishers B.V. All rights reserved. 0167-0115/92/$05.00

Author index

Absood, A., Chen, D. and Håkanson, R., Neuropeptides of the vasoactive intestinal peptide/helodermin/pituitary adenylate cyclase activating peptide family elevate plasma cAMP in mice: comparison with a range of other regulatory peptides, 311

Absood, A., Chen, D., Wang, Z.-Y. and Håkanson, R., Vascular effects of pituitary adenylate cyclase activating peptide: a comparison with vasoactive intestinal peptide, 323

Alexander, M., see Beardshall, K., 1

Andersson, M., Sillard, R. and Rökaeus, Å., Demonstration of [^{125}I]VIP binding sites and effects of VIP on cAMP-formation in rat insulinoma (RINm5F and RIN14B) cells, 41

Auberson, S., see Lacroix, J.-S., 373

Bateman, A., see Belcourt, D., 87

Beardshall, K., Deprez, P., Playford, R.J., Alexander, M. and Calam, J., Effect of chymotrypsin on human cholecystokinin release: use of clostripain in the validation of a new radioimmunoassay, 1

Belcourt, D., Singh, A., Bateman, A., Lazure, C., Solomon, S. and Bennett, H.P., Purification of cationic cystine-rich peptides from rat bone marrow. Primary structures and biological activity of the rat corticostatin family of peptides, 87

Bennett, H.P., see Belcourt, D., 87

Calam, J., see Beardshall, K., 1

Charles, C., see Yandle, T., 389

Chen, D., see Absood, A., 311

Chen, D., see Absood, A., 323

Coleman, J.K., see Swanson, G.N., 409

Cook, V.I., see Swanson, G.N., 409

Deprez, P., see Beardshall, K., 1

Desai, H., Uddman, R., Malina, J. and Sundler, F., Helospectin-like immunoreactivity in the esophagus, 363

Dockray, G.J., see Watkinson, A., 51

Edvinsson, L., see Gulbenkian, S., 351

Espiner, E., see Yandle, T., 389

Grundemar, L. and Håkanson, R., Unlike VIP, the VIP-related peptides PACAP, helodermin and helospectin suppress electrically evoked contractions of rat vas deferens, 331

Gulbenkian, S., Edvinsson, L., Saetrum Opgaard, O., Valença, A., Wharton, J. and Polak, J.M., Neuropeptide Y modulates the action of vasodilator agents in guinea-pig epicardial coronary arteries, 351

Guo, Y.-S., see Singh, P., 75

Håkanson, R., see Absood, A., 311

Håkanson, R., see Absood, A., 323

Håkanson, R., see Grundemar, L., 331

Hall, K.L., see Swanson, G.N., 409

Hanesworth, J.M., see Swanson, G.N., 409

Harding, E.C., see Swanson, G.N., 409

Harding, J.W., see Swanson, G.N., 409

Hökfelt, T., see Lacroix, J.-S., 373

Howells, R.D., see Rao, S.M., 397

Ishizuka, Y., Kashimoto, K., Mochizuki, T., Sato, K., Ohshima, K. and Yanaihara, N., Cardiovascular and respiratory actions of pituitary adenylate cyclase-activating polypeptides, 29

Kapuscinski, M., see Read, M.A., 13

Kashimoto, K., see Ishizuka, Y., 29

Kull, F.C., see Singh, P., 75

Lacroix, J.-S., Auberson, S., Morel, D.R., Theodorsson, E., Hökfelt, T. and Lundberg, J.M., Vascular control of the pig nasal mucosa: distribution and effect of somatostatin in relation to noradrenaline and neuropeptide Y, 373

Lazure, C., see Belcourt, D., 87

Leban, J.J., see Singh, P., 75

Litwin, D.K., Wilson, A.K. and Said, S.I., Vasoactive intestinal polypeptide (VIP) inhibits rat alveolar macrophage phagocytosis and chemotaxis in vitro, 63

Lundberg, J.M., see Lacroix, J.-S., 373

Malina, J., see Desai, H., 363

Miller-Wing, A.V., see Swanson, G.N., 409

Mochizuki, T., see Ishizuka, Y., 29

Morel, D.R., see Lacroix, J.-S., 373

Ohshima, K., see Ishizuka, Y., 29

Playford, R.J., see Beardshall, K., 1

Regulatory Peptides, 40 (1992) 422–423
© 1992 Elsevier Science Publishers B.V. All rights reserved. 0167-0115/92/$05.00

Author index

Absood, A., Chen, D. and Håkanson, R., Neuropeptides of the vasoactive intestinal peptide/helodermin/pituitary adenylate cyclase activating peptide family elevate plasma cAMP in mice: comparison with a range of other regulatory peptides, 311

Absood, A., Chen, D., Wang, Z.-Y. and Håkanson, R., Vascular effects of pituitary adenylate cyclase activating peptide: a comparison with vasoactive intestinal peptide, 323

Alexander, M., see Beardshall, K., 1

Andersson, M., Sillard, R. and Rökaeus, Å., Demonstration of [^{125}I]VIP binding sites and effects of VIP on cAMP-formation in rat insulinoma (RINm5F and RIN14B) cells, 41

Auberson, S., see Lacroix, J.-S., 373

Bateman, A., see Belcourt, D., 87

Beardshall, K., Deprez, P., Playford, R.J., Alexander, M. and Calam, J., Effect of chymotrypsin on human cholecystokinin release: use of clostripain in the validation of a new radioimmunoassay, 1

Belcourt, D., Singh, A., Bateman, A., Lazure, C., Solomon, S. and Bennett, H.P., Purification of cationic cystine-rich peptides from rat bone marrow. Primary structures and biological activity of the rat corticostatin family of peptides, 87

Bennett, H.P., see Belcourt, D., 87

Calam, J., see Beardshall, K., 1

Charles, C., see Yandle, T., 389

Chen, D., see Absood, A., 311

Chen, D., see Absood, A., 323

Coleman, J.K., see Swanson, G.N., 409

Cook, V.I., see Swanson, G.N., 409

Deprez, P., see Beardshall, K., 1

Desai, H., Uddman, R., Malina, J. and Sundler, F., Helospectin-like immunoreactivity in the esophagus, 363

Dockray, G.J., see Watkinson, A., 51

Edvinsson, L., see Gulbenkian, S., 351

Espiner, E., see Yandle, T., 389

Grundemar, L. and Håkanson, R., Unlike VIP, the VIP-related peptides PACAP, helodermin and helospectin suppress electrically evoked contractions of rat vas deferens, 331

Gulbenkian, S., Edvinsson, L., Saetrum Opgaard, O., Valença, A., Wharton, J. and Polak, J.M., Neuropeptide Y modulates the action of vasodilator agents in guinea-pig epicardial coronary arteries, 351

Guo, Y.-S., see Singh, P., 75

Håkanson, R., see Absood, A., 311

Håkanson, R., see Absood, A., 323

Håkanson, R., see Grundemar, L., 331

Hall, K.L., see Swanson, G.N., 409

Hanesworth, J.M., see Swanson, G.N., 409

Harding, E.C., see Swanson, G.N., 409

Harding, J.W., see Swanson, G.N., 409

Hökfelt, T., see Lacroix, J.-S., 373

Howells, R.D., see Rao, S.M., 397

Ishizuka, Y., Kashimoto, K., Mochizuki, T., Sato, K., Ohshima, K. and Yanaihara, N., Cardiovascular and respiratory actions of pituitary adenylate cyclase-activating polypeptides, 29

Kapuscinski, M., see Read, M.A., 13

Kashimoto, K., see Ishizuka, Y., 29

Kull, F.C., see Singh, P., 75

Lacroix, J.-S., Auberson, S., Morel, D.R., Theodorsson, E., Hökfelt, T. and Lundberg, J.M., Vascular control of the pig nasal mucosa: distribution and effect of somatostatin in relation to noradrenaline and neuropeptide Y, 373

Lazure, C., see Belcourt, D., 87

Leban, J.J., see Singh, P., 75

Litwin, D.K., Wilson, A.K. and Said, S.I., Vasoactive intestinal polypeptide (VIP) inhibits rat alveolar macrophage phagocytosis and chemotaxis in vitro, 63

Lundberg, J.M., see Lacroix, J.-S., 373

Malina, J., see Desai, H., 363

Miller-Wing, A.V., see Swanson, G.N., 409

Mochizuki, T., see Ishizuka, Y., 29

Morel, D.R., see Lacroix, J.-S., 373

Ohshima, K., see Ishizuka, Y., 29

Playford, R.J., see Beardshall, K., 1

Polak, J.M., see Gulbenkian, S., 351
Rao, S.M. and Howells, R.D., Molecular cloning, sequence analysis and translation of proenkephalin mRNA from rat heart, 397
Read, D.M., see Read, M.A., 13
Read, M.A., Read, D.M., Kapuscinski, M. and Shulkes, A., Achlorhydria induced changes in gastrin, somatostatin, H^+/K^+-ATPase and carbonic anhydrase in the sheep, 13
Richards, M., see Yandle, T., 389
Rökaeus, Å., see Andersson, M., 41
Sadler, B., see Yandle, T., 389
Saetrum Opgaard, O., see Gulbenkian, S., 351
Said, S.I., see Litwin, D.K., 63
Sardinia, M.F., see Swanson, G.N., 409
Sato, K., see Ishizuka, Y., 29
Shulkes, A., see Read, M.A., 13
Sillard, R., see Andersson, M., 41
Singh, A., see Belcourt, D., 87
Singh, P., Guo, Y.-S., Kull, F.C. and Leban, J.J., A novel bombesin receptor antagonist (2258U89), potently inhibits bombesin evoked release of gastrointestinal hormones from rats and dogs, in vitro and in vivo, 75
Sjöqvist, A., Difference between the antisecretory mechanisms of opioids and the somatostatin analogue octreotide in cholera toxin-induced small intestinal secretion in the rat, 339
Solomon, S., see Belcourt, D., 87
Stobb, J.W., see Swanson, G.N., 409
Sundler, F., see Desai, H., 363
Swanson, G.N., Hanesworth, J.M., Sardinia, M.F., Coleman, J.K., Wright, J.W., Hall, K.L., Miller-Wing, A.V., Stobb, J.W., Cook, V.I., Harding, E.C. and Harding, J.W., Discovery of a distinct binding site for angiotensin II (3–8), a putative angiotensin IV receptor, 409
Theodorsson, E., see Lacroix, J.-S., 373
Uddman, R., see Desai, H., 363
Valença, A., see Gulbenkian, S., 351
Wang, Z.-Y., see Absood, A., 323
Watkinson, A. and Dockray, G.J., Functional control of chromogranin A and B concentrations in the body of the rat stomach, 51
Wharton, J., see Gulbenkian, S., 351
Wilson, A.K., see Litwin, D.K., 63
Wright, J.W., see Swanson, G.N., 409
Yanaihara, N., see Ishizuka, Y., 29
Yandle, T., Sadler, B., Charles, C., Espiner, E. and Richards, M., Bivariate assay for cleaved atrial natriuretic factor (ANF(101–105/106–126)) in sheep plasma, 389

Regulatory Peptides, 40 (1992) 424–426
© 1992 Elsevier Science Publishers B.V. All rights reserved. 0167-0115/92/$05.00

Key word index

Acetylcholine; Neuropeptide Y; Vasoactive intestinal polypeptide; Calcitonin-gene related peptide; Substance P; Coronary innervation; Immunohistochemistry; In vitro pharmacology, 351

Adenylate cyclase; Cyclic AMP; PACAP; VIP; PTH; Plasma cAMP; Neuropeptide, 311

Adenylate cyclase; Vasoactive intestinal polypeptide; VIP-receptor; Beta-cell; Delta-cell; Insulin secretion, 41

α-Adrenergic; Morphine; Sympathetic, 339

Alveolar macrophage; Vasoactive intestinal polypeptide; Chemotaxis; Phagocytosis; Inflammation, 63

Angiotensin; Radioligand binding; Receptor autoradiography; Bovine adrenal; Renal blood flow, 409

Beta-cell; Vasoactive intestinal polypeptide; VIP-receptor; Delta-cell; Insulin secretion; Adenylate cyclase, 41

Blood pressure; Hypothalamic peptide; Pituitary adenylate cyclase-activating polypeptide; Vasoactive intestinal polypeptide (VIP); Femoral blood flow; Heart rate, 29

Bombesin receptor antagonist; Rat; Dog; Gastrin; Insulin; Pancreatic polypeptide, 75

Bovine adrenal; Radioligand binding; Receptor autoradiography; Angiotensin; Renal blood flow, 409

Calcitonin-gene related peptide; Neuropeptide Y; Vasoactive intestinal polypeptide; Substance P; Acetylcholine; Coronary innervation; Immunohistochemistry; In vitro pharmacology, 351

cAMP; VIP; PACAP; Vascular effect; Vasodepressor response; Vasodilatation, 323

Cardiac tissue; Transcription; Opioid peptide; Gene expression; Translation; Neuropeptide, 397

Chemotaxis; Vasoactive intestinal polypeptide; Alveolar macrophage; Phagocytosis; Inflammation, 63

Cholecystokinin; Radioimmunoassay; Proteinase; Chymotrypsin, 1

Chromogranin A; Chromogranin B; Omeprazole; Gastric fundus; Enterochromaffin-like cell; Food, 51

Chromogranin B; Chromogranin A; Omeprazole; Gastric fundus; Enterochromaffin-like cell; Food, 51

Chymotrypsin; Cholecystokinin; Radioimmunoassay; Proteinase, 1

Coronary innervation; Neuropeptide Y; Vasoactive intestinal polypeptide; Calcitonin-gene related peptide; Substance P; Acetylcholine; Immunohistochemistry; In vitro pharmacology, 351

Corticostatin; Rat bone marrow; Purification, 87

Cyclic AMP; Adenylate cyclase; PACAP; VIP; PTH; Plasma cAMP; Neuropeptide, 311

Delta-cell; Vasoactive intestinal polypeptide; VIP-receptor; Beta-cell; Insulin secretion; Adenylate cyclase, 41

Dog; Bombesin receptor antagonist; Rat; Gastrin; Insulin; Pancreatic polypeptide, 75

Electrically evoked twitch; Vasoactive intestinal peptide (VIP); Helodermin; Helospectin; Pituitary adenylate cyclase activating peptide (PACAP); Vas deferens; Receptor, 331

Endopeptidase; Radioimmunoassay; Metabolic clearance rate; Half-life, 389

Enterochromaffin-like cell; Chromogranin A; Chromogranin B; Omeprazole; Gastric fundus; Food, 51

Esophagus; Helospectin; VIP; NPY; SP; Neuropeptide; Peptide coexistence, 363

Femoral blood flow; Hypothalamic peptide; Pituitary adenylate cyclase-activating polypeptide; Vasoactive intestinal polypeptide (VIP); Blood pressure; Heart rate, 29

Food; Chromogranin A; Chromogranin B; Omeprazole; Gastric fundus; Enterochromaffin-like cell, 51

Gastric acid secretion; Omeprazole; Sheep, 13

Gastric fundus; Chromogranin A; Chromogran-

in B; Omeprazole; Enterochromaffin-like cell; Food, 51

Gastrin; Bombesin receptor antagonist; Rat; Dog; Insulin; Pancreatic polypeptide, 75

Gene expression; Transcription; Cardiac tissue; Opioid peptide; Translation; Neuropeptide, 397

Half-life; Radioimmunoassay; Endopeptidase; Metabolic clearance rate, 389

Heart rate; Hypothalamic peptide; Pituitary adenylate cyclase-activating polypeptide; Vasoactive intestinal polypeptide (VIP); Femoral blood flow; Blood pressure, 29

Helodermin; Vasoactive intestinal peptide (VIP); Helospectin; Pituitary adenylate cyclase activating peptide (PACAP); Electrically evoked twitch; Vas deferens; Receptor, 331

Helospectin; Vasoactive intestinal peptide (VIP); Helodermin; Pituitary adenylate cyclase activating peptide (PACAP); Electrically evoked twitch; Vas deferens; Receptor, 331

Helospectin; VIP; NPY; SP; Esophagus; Neuropeptide; Peptide coexistence, 363

Hypothalamic peptide; Pituitary adenylate cyclase-activating polypeptide; Vasoactive intestinal polypeptide (VIP); Femoral blood flow; Blood pressure; Heart rate, 29

Immunohistochemistry; Neuropeptide Y; Vasoactive intestinal polypeptide; Calcitonin-gene related peptide; Substance P; Acetylcholine; Coronary innervation; In vitro pharmacology, 351

Inflammation; Vasoactive intestinal polypeptide; Alveolar macrophage; Chemotaxis; Phagocytosis, 63

Insulin; Bombesin receptor antagonist; Rat; Dog; Gastrin; Pancreatic polypeptide, 75

Insulin secretion; Vasoactive intestinal polypeptide; VIP-receptor; Beta-cell; Delta-cell; Adenylate cyclase, 41

In vitro pharmacology; Neuropeptide Y; Vasoactive intestinal polypeptide; Calcitonin-gene related peptide; Substance P; Acetylcholine; Coronary innervation; Immunohistochemistry, 351

Metabolic clearance rate; Radioimmunoassay; Endopeptidase; Half-life, 389

Morphine; α-Adrenergic; Sympathetic, 339

Nasal mucosa; Pig; Noradrenaline; Neuropeptide Y; Somatostatin; Vasoactive Intestinal Polypeptide; Peptide histidine isoleucine; Vascular control, 373

Neuropeptide; Cyclic AMP; Adenylate cyclase; PACAP; VIP; PTH; Plasma cAMP, 311

Neuropeptide; Transcription; Cardiac tissue; Opioid peptide; Gene expression; Translation, 397

Neuropeptide; Helospectin; VIP; NPY; SP; Esophagus; Peptide coexistence, 363

Neuropeptide Y; Pig; Nasal mucosa; Noradrenaline; Somatostatin; Vasoactive Intestinal Polypeptide; Peptide histidine isoleucine; Vascular control, 373

Neuropeptide Y; Vasoactive intestinal polypeptide; Calcitonin-gene related peptide; Substance P; Acetylcholine; Coronary innervation; Immunohistochemistry; In vitro pharmacology, 351

Noradrenaline; Pig; Nasal mucosa; Neuropeptide Y; Somatostatin; Vasoactive Intestinal Polypeptide; Peptide histidine isoleucine; Vascular control, 373

NPY; Helospectin; VIP; SP; Esophagus; Neuropeptide; Peptide coexistence, 363

Omeprazole; Chromogranin A; Chromogranin B; Gastric fundus; Enterochromaffin-like cell; Food, 51

Omeprazole; Gastric acid secretion; Sheep, 13

Opioid peptide; Transcription; Cardiac tissue; Gene expression; Translation; Neuropeptide, 397

PACAP; Cyclic AMP; Adenylate cyclase; VIP; PTH; Plasma cAMP; Neuropeptide, 311

PACAP; VIP; Vascular effect; cAMP; Vasodepressor response; Vasodilatation, 323

Pancreatic polypeptide; Bombesin receptor antagonist; Rat; Dog; Gastrin; Insulin, 75

Peptide coexistence; Helospectin; VIP; NPY; SP; Esophagus; Neuropeptide, 363

Peptide histidine isoleucine; Pig; Nasal mucosa; Noradrenaline; Neuropeptide Y; Somatostatin; Vasoactive Intestinal Polypeptide; Vascular control, 373

Phagocytosis; Vasoactive intestinal polypeptide; Alveolar macrophage; Chemotaxis; Inflammation, 63

Pig; Nasal mucosa; Noradrenaline; Neuropeptide Y; Somatostatin; Vasoactive Intestinal Polypeptide; Peptide histidine isoleucine; Vascular control, 373

Pituitary adenylate cyclase activating peptide (PACAP); Vasoactive intestinal peptide (VIP); Helodermin; Helospectin; Electrically evoked twitch; Vas deferens; Receptor, 331

Pituitary adenylate cyclase-activating polypeptide; Hypothalamic peptide; Vasoactive intestinal polypeptide (VIP); Femoral blood flow; Blood pressure; Heart rate, 29

Plasma cAMP; Cyclic AMP; Adenylate cyclase; PACAP; VIP; PTH; Neuropeptide, 311
Proteinase; Cholecystokinin; Radioimmunoassay; Chymotrypsin, 1
PTH; Cyclic AMP; Adenylate cyclase; PACAP; VIP; Plasma cAMP; Neuropeptide, 311
Purification; Rat bone marrow; Corticostatin, 87
Radioimmunoassay; Endopeptidase; Metabolic clearance rate; Half-life, 389
Radioimmunoassay; Cholecystokinin; Proteinase; Chymotrypsin, 1
Radioligand binding; Receptor autoradiography; Bovine adrenal; Angiotensin; Renal blood flow, 409
Rat; Bombesin receptor antagonist; Dog; Gastrin; Insulin; Pancreatic polypeptide, 75
Rat bone marrow; Corticostatin; Purification, 87
Receptor; Vasoactive intestinal peptide (VIP); Helodermin; Helospectin; Pituitary adenylate cyclase activating peptide (PACAP); Electrically evoked twitch; Vas deferens, 331
Receptor autoradiography; Radioligand binding; Bovine adrenal; Angiotensin; Renal blood flow, 409
Renal blood flow; Radioligand binding; Receptor autoradiography; Bovine adrenal; Angiotensin, 409
Sheep; Gastric acid secretion; Omeprazole, 13
Somatostatin; Pig; Nasal mucosa; Noradrenaline; Neuropeptide Y; Vasoactive Intestinal Polypeptide; Peptide histidine isoleucine; Vascular control, 373
SP; Helospectin; VIP; NPY; Esophagus; Neuropeptide; Peptide coexistence, 363
Substance P; Neuropeptide Y; Vasoactive intestinal polypeptide; Calcitonin-gene related peptide; Acetylcholine; Coronary innervation; Immunohistochemistry; In vitro pharmacology, 351
Sympathetic; α-Adrenergic; Morphine, 339
Transcription; Cardiac tissue; Opioid peptide; Gene expression; Translation; Neuropeptide, 397
Translation; Transcription; Cardiac tissue; Opioid peptide; Gene expression; Neuropeptide, 397
Vascular control; Pig; Nasal mucosa; Noradrenaline; Neuropeptide Y; Somatostatin; Vasoactive Intestinal Polypeptide; Peptide histidine isoleucine, 373
Vascular effect; VIP; PACAP; cAMP; Vasodepressor response; Vasodilatation, 323
Vas deferens; Vasoactive intestinal peptide (VIP); Helodermin; Helospectin; Pituitary adenylate cyclase activating peptide (PACAP); Electrically evoked twitch; Receptor, 331
Vasoactive intestinal peptide (VIP); Helodermin; Helospectin; Pituitary adenylate cyclase activating peptide (PACAP); Electrically evoked twitch; Vas deferens; Receptor, 331
Vasoactive intestinal polypeptide; VIP-receptor; Beta-cell; Delta-cell; Insulin secretion; Adenylate cyclase, 41
Vasoactive intestinal polypeptide; Neuropeptide Y; Calcitonin-gene related peptide; Substance P; Acetylcholine; Coronary innervation; Immunohistochemistry; In vitro pharmacology, 351
Vasoactive intestinal polypeptide; Alveolar macrophage; Chemotaxis; Phagocytosis; Inflammation, 63
Vasoactive Intestinal Polypeptide; Pig; Nasal mucosa; Noradrenaline; Neuropeptide Y; Somatostatin; Peptide histidine isoleucine; Vascular control, 373
Vasoactive intestinal polypeptide (VIP); Hypothalamic peptide; Pituitary adenylate cyclase-activating polypeptide; Femoral blood flow; Blood pressure; Heart rate, 29
Vasodepressor response; VIP; PACAP; Vascular effect; cAMP; Vasodilatation, 323
Vasodilatation; VIP; PACAP; Vascular effect; cAMP; Vasodepressor response, 323
VIP; Cyclic AMP; Adenylate cyclase; PACAP; PTH; Plasma cAMP; Neuropeptide, 311
VIP; Helospectin; NPY; SP; Esophagus; Neuropeptide; Peptide coexistence, 363
VIP; PACAP; Vascular effect; cAMP; Vasodepressor response; Vasodilatation, 323
VIP-receptor; Vasoactive intestinal polypeptide; Beta-cell; Delta-cell; Insulin secretion; Adenylate cyclase, 41